Artivion, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2023
August 03, 2023 at 04:11 pm EDT
Share
Artivion, Inc. reported earnings results for the second quarter and six months ended June 30, 2023. For the second quarter, the company reported revenue was USD 89.25 million compared to USD 80.34 million a year ago. Net loss was USD 3.38 million compared to USD 4.26 million a year ago. Basic loss per share from continuing operations was USD 0.08 compared to USD 0.11 a year ago. Diluted loss per share from continuing operations was USD 0.08 compared to USD 0.11 a year ago.
For the six months, revenue was USD 172.48 million compared to USD 157.55 million a year ago. Net loss was USD 16.91 million compared to USD 7.65 million a year ago. Basic loss per share from continuing operations was USD 0.41 compared to USD 0.19 a year ago. Diluted loss per share from continuing operations was USD 0.41 compared to USD 0.19 a year ago.
Artivion, Inc. is a medical device company engaged in the manufacturing, processing, and distribution of medical devices and implantable human tissues used in cardiac and vascular surgical procedures for patients with aortic disease, heart valve disease, aortic aneurysms, and dissections. The Company's segments include Medical Devices and Preservation Services. The Medical Devices segment includes sales of aortic stent grafts, surgical sealants, and On-X. The Preservation Services segment includes services for the preservation of cardiac and vascular implantable human tissues. It has four product families: aortic stent grafts, surgical sealants, On-X mechanical heart valves and related surgical products, and implantable cardiac and vascular human tissues. Aortic stent grafts include aortic arch stent grafts, abdominal stent grafts, and synthetic vascular grafts. Surgical sealants include BioGlue Surgical Adhesive products. It also sells or distributes PhotoFix bovine surgical patches.
ARTIVION, INC. 
